MX351863B - Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. - Google Patents

Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.

Info

Publication number
MX351863B
MX351863B MX2014009991A MX2014009991A MX351863B MX 351863 B MX351863 B MX 351863B MX 2014009991 A MX2014009991 A MX 2014009991A MX 2014009991 A MX2014009991 A MX 2014009991A MX 351863 B MX351863 B MX 351863B
Authority
MX
Mexico
Prior art keywords
salt
quinolylpyrrolopyrimidyl
fused
ring compound
inhibition activity
Prior art date
Application number
MX2014009991A
Other languages
English (en)
Other versions
MX2014009991A (es
Inventor
Katsumasa Nonoshita
Takeshi Sagara
Sachie Otsuki
Satoru Ito
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2014009991A publication Critical patent/MX2014009991A/es
Publication of MX351863B publication Critical patent/MX351863B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente invención proporciona un nuevo compuesto que tiene una acción inhibitoria contra EGFR y que tiene efectos inhibitorios del crecimiento celular; la presente invención además proporciona una preparación farmacéutica útil para prevenir y/o tratar el cáncer, basado en el efecto inhibitorio del EGFR del compuesto; un compuesto representado por la siguiente fórmula (I) (ver Fórmula) o una sal del mismo.
MX2014009991A 2012-02-23 2013-02-22 Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. MX351863B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012037565 2012-02-23
PCT/JP2013/054615 WO2013125709A1 (ja) 2012-02-23 2013-02-22 キノリルピロロピリミジル縮合環化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2014009991A MX2014009991A (es) 2014-09-08
MX351863B true MX351863B (es) 2017-10-30

Family

ID=49005885

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009991A MX351863B (es) 2012-02-23 2013-02-22 Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.

Country Status (16)

Country Link
US (1) US8889666B2 (es)
EP (1) EP2722332B1 (es)
JP (1) JP5557963B2 (es)
KR (1) KR101660145B1 (es)
CN (1) CN104136438B (es)
CA (1) CA2861980C (es)
DK (1) DK2722332T3 (es)
ES (1) ES2580530T3 (es)
HK (1) HK1202862A1 (es)
HU (1) HUE029343T2 (es)
MX (1) MX351863B (es)
PL (1) PL2722332T3 (es)
RU (1) RU2581039C1 (es)
SG (1) SG11201402876UA (es)
TW (1) TWI496783B (es)
WO (1) WO2013125709A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015010934A (es) * 2013-02-22 2015-10-29 Taiho Pharmaceutical Co Ltd Metodo para producir un compuesto triciclico, y un compuesto triciclico capaz de producirse por dicho metodo de produccion.
US9650386B2 (en) 2013-08-22 2017-05-16 Taiho Pharmaceutical Co., Inc. Quinoline-substituted compound
PL3279202T3 (pl) * 2015-03-31 2020-12-28 Taiho Pharmaceutical Co., Ltd. Kryształ 3,5-dipodstawionego związku benzenoalkinylowego
WO2017064558A1 (ja) * 2015-10-14 2017-04-20 大鵬薬品工業株式会社 新規免疫賦活化剤
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
JP7065103B2 (ja) 2017-09-01 2022-05-11 大鵬薬品工業株式会社 エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
WO2021057796A1 (zh) * 2019-09-29 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN115785107A (zh) * 2022-12-15 2023-03-14 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011435A (es) * 2005-03-17 2007-12-05 Novartis Ag N-[3-(1-amino-5,6,7,8-tetrahidro-2,4,4b-triazafluoren-9-il)-fenil ]-benzamidas como inhibidores de cinasa de tirosina/treonina, en particular de cinasa b-raf.
US20080299113A1 (en) 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
EP2557080A1 (en) 2006-04-04 2013-02-13 The Regents of The University of California Method for identifying pI3-kinase antagonists
WO2008018881A1 (en) * 2006-08-10 2008-02-14 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
KR101315610B1 (ko) * 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2874756C (en) * 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
NZ627709A (en) * 2010-06-23 2014-12-24 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
TWI545115B (zh) * 2010-11-01 2016-08-11 阿維拉製藥公司 雜環化合物及其用途

Also Published As

Publication number Publication date
KR101660145B1 (ko) 2016-09-26
CN104136438A (zh) 2014-11-05
KR20140117647A (ko) 2014-10-07
MX2014009991A (es) 2014-09-08
CA2861980C (en) 2016-11-08
DK2722332T3 (en) 2016-06-20
CN104136438B (zh) 2016-04-06
TWI496783B (zh) 2015-08-21
PL2722332T3 (pl) 2016-10-31
EP2722332A4 (en) 2014-04-23
EP2722332A1 (en) 2014-04-23
SG11201402876UA (en) 2014-12-30
US20140057899A1 (en) 2014-02-27
WO2013125709A1 (ja) 2013-08-29
AU2013223052A1 (en) 2014-07-03
EP2722332B1 (en) 2016-04-20
HK1202862A1 (zh) 2015-10-09
JP5557963B2 (ja) 2014-07-23
ES2580530T3 (es) 2016-08-24
TW201339160A (zh) 2013-10-01
RU2581039C1 (ru) 2016-04-10
JPWO2013125709A1 (ja) 2015-07-30
CA2861980A1 (en) 2013-08-29
HUE029343T2 (en) 2017-02-28
US8889666B2 (en) 2014-11-18

Similar Documents

Publication Publication Date Title
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
PH12017502141A1 (en) Compounds and their methods of use
PH12016500225A1 (en) Novel quinoline-substituted compound
PH12015501058A1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
TN2012000401A1 (en) Heterocyclic compound
MD4659B1 (ro) Polimorf al inhibitorilor SYK
MX2016006336A (es) Compuestos pirazolopirimidina.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2015DN00827A (es)
MY162933A (en) Chemical compounds
GEP201706725B (en) Compounds and compositions as inhibitors of mek
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
PH12015501038A1 (en) Inhibitors of iap
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
MX346095B (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
NZ709094A (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration